Bleomycin induzierte Pneumonitis

Bleomycin lung toxicity is an uncommon but recognized complication that can occur with the chemotherapeutic drug bleomycin.

Pathology

Bleomycin

Bleomycin is an antitumour antibiotic which was initially isolated from a strain of Streptomyces verticillus in 1966. It is commonly used (either alone or in combination with other chemotherapeutic agents) in the treatment of squamous cell carcinomas (of the head and neck, cervix, and vagina), testicular cancer, and Hodgkin lymphoma.

Epidemiology

Bleomycin-induced lung injury usually occurs in 3-18% of treated patients (this figure will vary dependent on detection method used), although there is a marked increased risk if the total cumulative dose is more than 450 units.

The risk of developing lung injury is increased in the elderly and in patients receiving oxygen therapy, with a history of prior thoracic irradiation, or in whom therapy is re-instituted within 6 months of discontinuation.

Radiographic features

CT

On HRCT chest it can manifest in several patterns that include:

• diffuse alveolar damage
• pulmonary fibrosis
• organizing pneumonia pattern 
• NSIP pattern 
• bronchiolitis obliterans organizing pneumonia pattern
  • may present as nodules which range from 5 mm to 3 cm in diameter
  • are usually subpleural in location, and can be sharply or poorly marginated

Treatment and prognosis

The prognosis is poor, with most patients dying of respiratory failure within 3 months of onset of symptoms.

Siehe auch:

• Kryptogene organisierende Pneumonie (COP)
• Pneumonitis
• non specific interstitial pneumonia (NSIP)
• medikamenteninduzierte Pneumonitis
• diffuser Alveolarschaden
• Bleomycin